{
    "xml": "<topic id=\"PHP3804\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/fosamprenavir\" basename=\"fosamprenavir\" title=\"FOSAMPRENAVIR\">\n<title>FOSAMPRENAVIR</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1019\" namespace=\"/interactions/list-of-drug-interactions/antivirals/fosamprenavir\">Fosamprenavir</xref>\n</p>\n<data name=\"vtmid\">407018001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_643762552\" title=\"Protease inhibitors (HIV)\">Protease inhibitors (HIV)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34642\" title=\"PROTEASE INHIBITORS\" namespace=\"/drug-classes/protease-inhibitors\">PROTEASE INHIBITORS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP65590\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/fosamprenavir\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Fosamprenavir is a pro-drug of amprenavir.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65505\" outputclass=\"indicationsAndDose\" rev=\"1.25\" parent=\"/drugs/fosamprenavir\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">HIV infection in combination with other antiretroviral drugs&#8212;with low-dose ritonavir</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>700&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>700&#8239;mg fosamprenavir is equivalent to approximately 600&#8239;mg amprenavir.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65455\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/fosamprenavir\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (fosamprenavir).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65377\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/drugs/fosamprenavir\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Rash</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Rash</p>\n<p>Rash may occur, usually in the second week of therapy; discontinue permanently if severe rash with systemic or allergic symptoms or, mucosal involvement; if rash mild or moderate, may continue without interruption&#8212;usually resolves within 2 weeks and may respond to antihistamines.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65423\" outputclass=\"pregnancy\" parent=\"/drugs/fosamprenavir\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Toxicity in <i>animal</i> studies; manufacturer advises use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65528\" outputclass=\"hepaticImpairment\" parent=\"/drugs/fosamprenavir\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose to 450&#8239;mg twice daily in moderate impairment; reduce dose to 300&#8239;mg twice daily in severe impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in mild impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65767\" outputclass=\"directionsForAdministration\" rev=\"1.8\" parent=\"/drugs/fosamprenavir\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>In adults, oral suspension should be taken on an empty stomach.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58616\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.11\" parent=\"/drugs/fosamprenavir\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Flavours of oral liquid formulations may include grape, bubblegum, or peppermint.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65394\" outputclass=\"patientAndCarerAdvice\" rev=\"1.9\" parent=\"/drugs/fosamprenavir\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients or carers should be given advice on how to administer fosamprenavir oral suspension.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3804-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/fosamprenavir\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77014\" title=\"Tablet\" namespace=\"/drugs/fosamprenavir/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77022\" title=\"Oral suspension\" namespace=\"/drugs/fosamprenavir/oral-suspension\">Oral suspension</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78275\" namespace=\"/treatment-summaries/hiv-infection\" title=\"HIV infection\" count=\"3\" rel=\"backlink\">HIV infection</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1019\" namespace=\"/interactions/list-of-drug-interactions/antivirals/fosamprenavir\" title=\"Fosamprenavir\" count=\"1\" rel=\"link\">Fosamprenavir</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34642\" namespace=\"/drug-classes/protease-inhibitors\" title=\"PROTEASE INHIBITORS\" count=\"1\" rel=\"link\">PROTEASE INHIBITORS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77014\" namespace=\"/drugs/fosamprenavir/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77022\" namespace=\"/drugs/fosamprenavir/oral-suspension\" title=\"Oral suspension\" count=\"1\" rel=\"link\">Oral suspension</xref>\n</links>\n</topic>",
    "id": "PHP3804",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/fosamprenavir",
    "basename": "fosamprenavir",
    "title": "FOSAMPRENAVIR",
    "interactants": [
        {
            "id": "bnf_int_1019",
            "label": "Fosamprenavir"
        }
    ],
    "vtmid": "407018001",
    "drugClassification": [
        "Protease inhibitors (HIV)"
    ],
    "inheritsFromClass": [
        "PROTEASE INHIBITORS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Fosamprenavir is a pro-drug of amprenavir.",
                "html": "<p>Fosamprenavir is a pro-drug of amprenavir.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "HIV infection in combination with other antiretroviral drugs&#8212;with low-dose ritonavir",
                        "html": "HIV infection in combination with other antiretroviral drugs&#8212;with low-dose ritonavir"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "700 mg twice daily.",
                        "html": "<p>700&#8239;mg twice daily.</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "700 mg fosamprenavir is equivalent to approximately 600 mg amprenavir.",
                "html": "<p>700&#8239;mg fosamprenavir is equivalent to approximately 600&#8239;mg amprenavir.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (fosamprenavir).",
                "html": "<p>Appendix 1 (fosamprenavir).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Rash",
                        "html": "Rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Rash",
                "textContent": "Rash may occur, usually in the second week of therapy; discontinue permanently if severe rash with systemic or allergic symptoms or, mucosal involvement; if rash mild or moderate, may continue without interruption&#8212;usually resolves within 2 weeks and may respond to antihistamines.",
                "html": "<p>Rash may occur, usually in the second week of therapy; discontinue permanently if severe rash with systemic or allergic symptoms or, mucosal involvement; if rash mild or moderate, may continue without interruption&#8212;usually resolves within 2 weeks and may respond to antihistamines.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Toxicity in animal studies; manufacturer advises use only if potential benefit outweighs risk.",
                "html": "<p>Toxicity in <i>animal</i> studies; manufacturer advises use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose to 450 mg twice daily in moderate impairment; reduce dose to 300 mg twice daily in severe impairment.",
                "html": "<p>Reduce dose to 450&#8239;mg twice daily in moderate impairment; reduce dose to 300&#8239;mg twice daily in severe impairment.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in mild impairment.",
                "html": "<p>Manufacturer advises caution in mild impairment.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "In adults, oral suspension should be taken on an empty stomach.",
                "html": "<p>In adults, oral suspension should be taken on an empty stomach.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Flavours of oral liquid formulations may include grape, bubblegum, or peppermint.",
                "html": "<p>Flavours of oral liquid formulations may include grape, bubblegum, or peppermint.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients or carers should be given advice on how to administer fosamprenavir oral suspension.",
                "html": "<p>Patients or carers should be given advice on how to administer fosamprenavir oral suspension.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77014",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77022",
                "label": "Oral suspension",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78275",
                "label": "HIV infection",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1019",
                "label": "Fosamprenavir",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34642",
                "label": "PROTEASE INHIBITORS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77014",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77022",
                "label": "Oral suspension",
                "type": "medicinalForm"
            }
        ]
    }
}